Table 1.
Trade name1 | FDC2 | Concentration | Manufacturer |
---|---|---|---|
Dual combinations | |||
Coviro-LS Kid | d4T+3TC | 5 mg+20 mg | Ranbaxy, India |
Coviro-LS Kid DS | d4T+3TC | 10 mg+40 mg | Ranbaxy, India |
Emduo Junior | d4T+3TC | 10 mg+40 mg | Emcure, India |
Emduo Suspension | d4T+3TC | 10 mg+40 mg per 5 ml | Emcure, India |
Lamivir S Baby | d4T+3TC | 6 mg+30 mg | Cipla, India |
Lamivir S Junior | d4T+3TC | 12 mg+60 mg | Cipla, India |
Triple combinations | |||
Emtri Junior | d4T+3TC+NVP | 10 mg+40 mg+70 mg | Emcure, India |
Emtri Suspension | d4T+3TC+NVP | 10 mg+40 mg+70 mg per 5 ml | Emcure, India |
GPOvir-S73 | d4T+3TC+NVP | 7 mg+30 mg+50 mg | GPO, Thailand |
Triommune Baby4 | d4T+3TC+NVP | 6 mg+30 mg+50 mg | Cipla, India |
Triommune Junior4 | d4T+3TC+NVP | 12 mg+60 mg+100 mg | Cipla, India |
Triviro-LNS Kid5 | d4T+3TC+NVP | 5 mg+20 mg+35 mg | Ranbaxy, India |
Triviro-LNS Kid DS5 | d4T+3TC+NVP | 10 mg+40 mg+70 mg | Ranbaxy, India |
Avocomb-N Kid5 | AZT+3TC+NVP | 60 mg+30 mg+60 mg | Ranbaxy, India |
GPOvir-Z306 | AZT+3TC+NVP | 30 mg+15 mg+28 mg | GPO, Thailand |
All drugs are in tablet form, unless otherwise noted.
d4T – stavudine; 3TC – lamivudine; NVP – nevirapine; AZT – zidovudine.
Phase I/II
FDA tentative approval and WHO prequalified
Under WHO review
Phase I, 2008 (planned)